Summary: Cell, gene and immuno-oncology therapies provide the biggest potential for previously incurable conditions and are the future of medicine and healthcare. The complexity of these therapeutics poses...
Summary:
"What is happening now is a species-altering event..."
A dramatic but nonetheless true statement from Bernard Siegel, Founder of the World Stem Cell Summit. The advanced therapies revolution...
Summary: The trial design for an immuno-oncology therapy can often be as complicated as the science itself! Designing effective clinical trials and translational models is a top priority for anyone in the...
Summary: Susan Nichols, CEO of Falcon Therapeutics provides sharp insight and expertise on three different types of partnerships that are crucial for a small biotech's success in advanced therapies.
Academic...
Summary: Matthew Durdy, CBO at the Cell and Gene Therapy Catapult leads a panel of cell and gene therapy manufacturing global experts to discuss Phacilitate's 2017 Automation special interest group findings...
Summary: So much has happened in the immuno-oncology industry since we spoke to Peter at IO Frontiers World 2017 in Miami. However, the balance between opportunities and challenges remains and we still need...
Summary:
The story of Japan’s regulatory reform is broken down into four sections:
1. The rationale behind the reform
Dr Yamanaka’s Nobel Prize win in (and huge national pride), plus an ageing...
Summary: A lot of the discussion around the development of Immuno-oncology therapies centres on ‘the science’ but what of the infrastructure for delivering these treatments?
Without clear plans for...
Summary:
This episode covers three big success factors of global tech transfer
1. Process vs product
Does IP lie in the process or the product? Find out what Ohad thinks is a ‘big mistake’ and where IP...
Summary: “Developers often say to me that the common technical document module three just doesn’t make any sense; it just doesn’t fit cell and gene therapy products…”
This video provides a guide to the...
